share_log

DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

德桑蒂斯政府警告對於脆弱個體不要使用輝瑞、moderna mRNA新冠疫苗,引用了與罕見心臟狀況相關的擔憂。
Benzinga ·  09/16 11:18

Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.

據報道,佛羅里達州州長羅恩·德桑提斯的政府已發佈更新指南,建議醫療提供者將易感患者從mRNA基因的COVID-19疫苗中移開。

The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.

佛羅里達衛生部對mRNA疫苗的安全性提出了擔憂,指出潛在風險,如心肌炎和姿勢性體位性心動過速綜合徵(POTS),這些是罕見的心臟疾病。這一立場與聯邦衛生機構的建議形成鮮明對比,後者繼續推薦mRNA疫苗對所有符合條件的人群安全有效。

In June, the U.S. CDC recommended using updated 2024-2025 COVID-19 vaccines in individuals six months and older.

六月,美國CDC建議對六個月及以上的個體使用更新的2024-2025年COVID-19疫苗。

The FDA in August granted emergency use approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and Pfizer Inc (NYSE:PFE)/BioNTech SE's (NASDAQ:BNTX), targeting the Omicron variant KP.2 strain.

FDA於八月批准了Moderna公司(NASDAQ:MRNA)和Pfizer公司(NYSE:PFE)/BioNTech公司(NASDAQ:BNTX)基於mRNA的COVID-19疫苗的緊急使用許可,針對Omicron變異KP.2株。

Also Read: Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows.

還可閱讀:長期COVID依然是診斷難題,診斷仍然難以確定;由國家衛生研究院資助的研究顯示。

The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.

NBC新聞指出,該州衛生部建議年齡在65歲及以上的人群以及具有基礎健康問題的人優先選擇非mRNA疫苗和治療手段。

Earlier this month, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:NVAX) protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.

本月初,FDA授權Novavax公司(NASDAQ:NVAX)蛋白質基COVID-19疫苗,佐劑(2024-2025配方)(NVX-CoV2705)用於12歲及以上人群的主動免疫預防COVID-19。

The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.

該州的指南強調,根據先前感染的高免疫水平以及當前數據,他們的立場是合理的。

The report adds that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.

報告指出,雖然mRNA疫苗與心肌炎有小概率關聯,尤其是在年輕男性身上,但研究顯示大多數病例都很輕微並完全恢復。

Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.

《自然心血管研究》發表的研究強調,感染COVID-19的個體患上POTS的幾率是接種mRNA疫苗的人的五倍,進一步強調了接種疫苗的重要性。

Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of heart attacks and strokes.

劍橋、布里斯托和愛丁堡大學的研究人員揭示COVID-19疫苗可能會顯著降低動脈血栓發生的概率,動脈血栓是心臟病發作和中風的主要原因。

Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.

股票表現:MRNA股票上漲2.37%,至69.90美元,PFE股票上漲2.12%,至29.89美元,以上爲週一最新數據。

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

免責聲明:本內容部分使用人工智能工具生成,並經Benzinga編輯審核發佈。

  • BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report.
  • BHP集團對銅供應發出警告,人工智能和電動汽車的增長可能會推高價格。

Image via Shutterstock

圖片來自shutterstock。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論